Protean Agonism at the Dopamine D2 Receptor: (S)-3-(3-Hydroxyphenyl)-N-propylpiperidine Is an Agonist for Activation of Go1 but an Antagonist/Inverse Agonist for Gi1,Gi2, and Gi3
Open Access
- 1 May 2007
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 71 (5) , 1349-1359
- https://doi.org/10.1124/mol.106.032722
Abstract
A range of ligands displayed agonism at the long isoform of the human dopamine D2 receptor, whether using receptor-G protein fusions or membranes of cells in which pertussis toxin-resistant mutants of individual Gαi-family G proteins could be expressed in an inducible fashion. Varying degrees of efficacy were observed for individual ligands as monitored by their capacity to load [35S]GTPγS onto each of Gαi1,Gαi2,Gαi3, and Gαo1. By contrast, (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine was a partial agonist when Gαo1 was the target G protein but an antagonist/inverse agonist at Gαi1,Gαi2, and Gαi3. In ligand binding assays, dopamine identified both high- and low-affinity states at each of the dopamine D2 receptor-G protein fusion proteins, and the high-affinity state was eliminated by guanine nucleotide. (S)-(–)-3-(3-Hydroxyphenyl)-N-propylpiperidine bound to an apparent single state of the constructs in which the D2 receptor was fused to Gαi1,Gαi2, or Gαi3. However, it bound to distinct high- and low-affinity states of the D2 receptor-Gαo1 fusion, with the high-affinity state being eliminated by guanine nucleotide. Likewise, although dopamine identified guanine nucleotide-sensitive high-affinity states of the D2 receptor when expression of pertussis toxin-resistant forms of each of Gαi1, Gαi2, Gαi3, and Gαo1 was induced, (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine identified a high-affinity site only in the presence of Gαo1. p-Tyramine displayed a protean ligand profile similar to that of (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine but with lower potency. These results demonstrate (S)-(–)-3-(3-hydroxyphenyl)-N-propylpiperidine to be a protean agonist at the D2 receptor and may explain in vivo actions of this ligand.This publication has 39 references indexed in Scilit:
- Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin releaseEuropean Journal of Pharmacology, 2006
- Inverse agonist properties of atypical antipsychotic drugsBiochemical Pharmacology, 2004
- β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptorsProceedings of the National Academy of Sciences, 2003
- Modulation of 5-HT1A receptor activation by its interaction with wild-type and mutant Gαi3 proteinsNeuropharmacology, 2001
- Agonist Regulation of D2 Dopamine Receptor/G Protein InteractionJournal of Biological Chemistry, 2001
- The Regulator of G Protein Signaling RGS4 Selectively Enhances α2A-Adreoreceptor Stimulation of the GTPase Activity of Go1α and Gi2αPublished by Elsevier ,2000
- Hydrophobicity of Residue351 of the G Protein Gi1α Determines the Extent of Activation by the α2A-AdrenoceptorBiochemistry, 1998
- Effector Pathway-Dependent Relative Efficacy at Serotonin Type 2A and 2C Receptors: Evidence for Agonist-Directed Trafficking of Receptor StimulusMolecular Pharmacology, 1998
- Human 5-HT1 Receptor Subtypes Exhibit Distinct G Protein Coupling Behaviors in Membranes from Sf9 CellsBiochemistry, 1997
- Light and electron microscopic localization of α subunits of GTP-binding proteins, G0 and G1, in the cerebral cortex and hippocampus of rat brainBrain Research, 1992